Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5411544

O=C(O)C(F)(F)F.O=C([C@@H]1CCCN1)N1CCCC1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 8/20 0.53
DPP8 Q6V1X1 5/20 0.53
DPP9 Q86TI2 4/20 0.53
FAP Q12884 1/20 0.44
DPP7 Q9UHL4 1/20 0.44
WNT3 P56703 2/20 0.43
SFRP1 Q8N474 2/20 0.43
HPGD P15428 1/20 0.39
HDAC2 Q92769 1/20 0.38
ARG1 P05089 2/20 0.38
ARG2 P78540 1/20 0.38
PARP1 P09874 1/20 0.38
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38
TGM2 P21980 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383434 0.88 DPP4 (0.64) DPP4DPP8DPP9FAPDPP7
SCHEMBL488953 0.88 DPP4 (0.64) DPP4DPP8DPP9FAPDPP7
SCHEMBL488954 0.88 DPP4 (0.64) DPP4DPP8DPP9FAPDPP7
Hydrochloric Acid SCHEMBL5413834 0.86 DPP4 (0.62) DPP4DPP8DPP9FAPDPP7
SCHEMBL10326191 0.86 DPP4 (0.62) DPP4DPP8DPP9FAPDPP7
SCHEMBL3335449 0.86 DPP4 (0.62) DPP4DPP8DPP9FAPDPP7
SCHEMBL3331450 0.86 DPP4 (0.62) DPP4DPP8DPP9FAPDPP7
SCHEMBL14548972 0.86 DPP4 (0.62) DPP4DPP8DPP9FAPDPP7
SCHEMBL3332858 0.84 DPP4 (0.64) DPP4DPP8DPP9FAPDPP7
SCHEMBL3332865 0.84 DPP4 (0.64) DPP4DPP8DPP9FAPDPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7173024-B2 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use ORION CORPORATION (FI) 2007-02-06 US disclosed
US-20050020677-A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use ORION CORPORATION (FI) 2005-01-27 US disclosed
WO-2004076434-A1 DIPEPTIDYL PEPTIDASE INHIBITORS AIC (BE) 2004-09-10 WO disclosed
EP-1401810-A1 COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE ORION CORPORATION (FI) 2004-03-31 EP disclosed
WO-2003004468-A1 COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE ORION CORPORATION (FI) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020677-A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use DNPEP, PREP, ANPEP DPP4 45/4885DPP8 55/4885DPP9 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.